THERAPEUTIC CLASS

Genetics of NO Deficiency

---

Nitric oxide-cyclic guanosine monophosphate (NO-cGMP) deficiency has been associated with an increased risk for cardiovascular disease (CVD).1,2 The term NO-cGMP de-
ficiency refers to conditions that lead to the impaired bioavailability and bioactivity of NO and/or cGMP and involves mechanisms including endothelial NO-synthase (eNOS)
substrate deficiency and/or competition, eNOS defects and/ or uncoupling, endogenous NOS inhibitors (such as asymmetric dimethylarginine [ADMA]), and diminished gen-
eration and/or enhanced degradation of cGMP. These conditions can be either acquired or inherited (genetic).

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Cardiovascular & Hematopoeiteic System

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment